We want to keep you informed about recent regulatory changes affecting compounded semaglutide. This medication is being removed from the short list, meaning pharmacies will soon face limited or no access to compounded versions. As a result, many patients currently using compounded semaglutide will need to transition to alternative treatments in the coming months.
While some patients may still qualify for compounded semaglutide under specific clinical circumstances, most will need to explore alternative options. Now is the time to start conversations with your patients to help them navigate this transition smoothly. Start maximizing GLP-1 utilization while the opportunity is still available.
How to Prepare Your Pharmacy:
✅ Explore Alternative Medications – Consider offering other compounded options available or commercially available weight loss treatments, including oral medications and liraglutide, which is expected to become more widely accessible. Read more...
✅ Proactive Patient Communication – Start notifying patients now about these changes so they can prepare for adjustments to their treatment plan. Use digital solutions like social media, email, and in-store communication to educate them on available alternatives.
✅ Leverage Telemedicine – If you offer XPedicareRx-24, use our custom telemedicine services to help patients consult with providers and find the best treatment option. With over 110 compound templates, it’s never been easier to engage patients.
✅ Reliable GLP-1 Supply – Stay ahead of the demand with access to a trusted 503B supplier. Get started with as little as 5 vials (Mix & Match) for as low as $55—the more you stock, the more you save!
Weight loss remains one of the highest-demand categories, and despite these changes, we are committed to helping your pharmacy thrive. If you have any questions or need assistance in adjusting your offerings, our team is here to help! Schedule a call
Let’s work together to ensure a smooth transition for your patients.
Commentaires